title: Radiation dose and risk of soft tissue and bone sarcoma after breast cancer treatment.
abstract: BACKGROUND
  To quantify the risk of soft tissue and bone sarcomas after breast cancer according to the doses and technical modalities of irradiation.
  
  
  METHODS
  We followed a cohort of 6597 breast-cancer patients for 8.3 years on average. The number of soft tissue and bone sarcomas was compared to the expected number based on the incidence rates in the general French population. We also estimated the risk of sarcoma according to the radiation dose received at site of the sarcoma in a nested case control study of 14 breast-cancer patients who subsequently developed a sarcoma and 98 controls matched for age at diagnosis of breast cancer, period of initial treatment and length of follow-up.
  
  
  RESULTS
  In the cohort-study, 12 women who had initially received radiotherapy treatment developed a bone or soft tissue sarcoma during the follow-up period. The expected number of cases during this period was 1.7 (SIR = 7.0, 95% CI: 3.7-11.7) and the mean annual excess incidence during the same period was 21 per 100,000 person-years. The 15-year cumulative incidence of sarcoma was 0.28% (95% CI: 0.10-0.45%). In the case-control study, all the 14 cases had received at least 11.8 Gray at the site of the sarcoma, which was always located in the irradiated field or in the upper ipsilateral extremity of the arm. A dose-effect relationship was observed (p < 0.001). The best fit was obtained for a quadratic dose-response relationship, without a negative exponential term for cell killing at high doses. The risk of sarcoma was 30.6 higher for doses of more than 44 Gray than for doses of less than 15 Gray.
  
  
  CONCLUSIONS
  High doses of radiation strongly increase the risk of bone and soft tissue sarcoma.
authors.affiliation: Unit of Cancer Epidemiology, National Institute of Health and Medical Research (U605 INSERM), Villejuif, France.
authors.forename: Carole
authors.initials: C
authors.lastname: Rubino
authors.forename: Akthar
authors.initials: A
authors.lastname: Shamsaldin
authors.forename: Monique G
authors.initials: MG
authors.lastname: Lê
authors.forename: Martine
authors.initials: M
authors.lastname: Labbé
authors.forename: Jean-Marc
authors.initials: JM
authors.lastname: Guinebretière
authors.forename: Jean
authors.initials: J
authors.lastname: Chavaudra
authors.forename: Florent
authors.initials: F
authors.lastname: de Vathaire
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000209:etiology*; D001943:Breast Neoplasms / Q000532:radiotherapy*; D016022:Case-Control Studies; D015331:Cohort Studies; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009381:Neoplasms, Radiation-Induced / Q000209:etiology*; D016609:Neoplasms, Second Primary / Q000209:etiology*; D011878:Radiotherapy / Q000009:adverse effects; D011879:Radiotherapy Dosage; D012307:Risk Factors; D012509:Sarcoma / Q000209:etiology*; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal